News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
PEEK brings a new quality to dental care for patients
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Subscribe To Our Newsletter & Stay Updated
